These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37184523)

  • 21. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial.
    Kuiper EM; van Erpecum KJ; Beuers U; Hansen BE; Thio HB; de Man RA; Janssen HL; van Buuren HR
    Hepatology; 2010 Oct; 52(4):1334-40. PubMed ID: 20683930
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.
    Wunsch E; Trottier J; Milkiewicz M; Raszeja-Wyszomirska J; Hirschfield GM; Barbier O; Milkiewicz P
    Hepatology; 2014 Sep; 60(3):931-40. PubMed ID: 24519384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study.
    Assis DN; Abdelghany O; Cai SY; Gossard AA; Eaton JE; Keach JC; Deng Y; Setchell KD; Ciarleglio M; Lindor KD; Boyer JL
    J Clin Gastroenterol; 2017 Feb; 51(2):e11-e16. PubMed ID: 27428727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus.
    Hegade VS; Pechlivanis A; McDonald JAK; Rees D; Corrigan M; Hirschfield GM; Taylor-Robinson SD; Holmes E; Marchesi JR; Kendrick S; Jones DE
    Liver Int; 2019 May; 39(5):967-975. PubMed ID: 30735608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH.
    Xu J; Wang Y; Khoshdeli M; Peach M; Chuang JC; Lin J; Tsai WW; Mahadevan S; Minto W; Diehl L; Gupta R; Trauner M; Patel K; Noureddin M; Kowdley KV; Gulamhusein A; Bowlus CL; Huss RS; Myers RP; Chung C; Billin AN
    Hepatology; 2023 Jan; 77(1):20-32. PubMed ID: 35686937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of 6-year event-free survival in Alagille syndrome patients treated with maralixibat, an ileal bile acid transporter inhibitor.
    Sokol RJ; Gonzales EM; Kamath BM; Baker A; Vig P; Mogul DB; Garner W; Hansen BE; Jacquemin E; Thompson RJ
    Hepatology; 2023 Dec; 78(6):1698-1710. PubMed ID: 37278241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A pilot study of etanercept in the treatment of primary sclerosing cholangitis.
    Epstein MP; Kaplan MM
    Dig Dis Sci; 2004 Jan; 49(1):1-4. PubMed ID: 14992426
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis.
    Tabibian JH; Gossard A; El-Youssef M; Eaton JE; Petz J; Jorgensen R; Enders FB; Tabibian A; Lindor KD
    Am J Ther; 2017; 24(1):e56-e63. PubMed ID: 24914504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.
    Hirschfield GM; Chazouillères O; Drenth JP; Thorburn D; Harrison SA; Landis CS; Mayo MJ; Muir AJ; Trotter JF; Leeming DJ; Karsdal MA; Jaros MJ; Ling L; Kim KH; Rossi SJ; Somaratne RM; DePaoli AM; Beuers U
    J Hepatol; 2019 Mar; 70(3):483-493. PubMed ID: 30414864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Placebo-Controlled Randomized Trial of an Intestinal Bile Salt Transport Inhibitor for Pruritus in Alagille Syndrome.
    Shneider BL; Spino C; Kamath BM; Magee JC; Bass LM; Setchell KD; Miethke A; Molleston JP; Mack CL; Squires RH; Murray KF; Loomes KM; Rosenthal P; Karpen SJ; Leung DH; Guthery SL; Thomas D; Sherker AH; Sokol RJ;
    Hepatol Commun; 2018 Oct; 2(10):1184-1198. PubMed ID: 30288474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: A systematic review and meta-analysis.
    Liu X; Wang H; Liu X; Bridle K; Crawford D; Liang X
    Pharmacol Ther; 2022 Sep; 237():108163. PubMed ID: 35271884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monoacylglycerol Lipase Inhibition Protects From Liver Injury in Mouse Models of Sclerosing Cholangitis.
    Tardelli M; Bruschi FV; Fuchs CD; Claudel T; Auer N; Kunczer V; Baumgartner M; A H O Ronda O; Verkade HJ; Stojakovic T; Scharnagl H; Habib A; Zimmermann R; Lotersztajn S; Trauner M
    Hepatology; 2020 May; 71(5):1750-1765. PubMed ID: 31505038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel Aspects in the Management of Cholestatic Liver Diseases.
    Chazouillères O
    Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial.
    Thompson RJ; Arnell H; Artan R; Baumann U; Calvo PL; Czubkowski P; Dalgic B; D'Antiga L; Durmaz Ö; Fischler B; Gonzalès E; Grammatikopoulos T; Gupte G; Hardikar W; Houwen RHJ; Kamath BM; Karpen SJ; Kjems L; Lacaille F; Lachaux A; Lainka E; Mack CL; Mattsson JP; McKiernan P; Özen H; Rajwal SR; Roquelaure B; Shagrani M; Shteyer E; Soufi N; Sturm E; Tessier ME; Verkade HJ; Horn P
    Lancet Gastroenterol Hepatol; 2022 Sep; 7(9):830-842. PubMed ID: 35780807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A pilot study of vidofludimus calcium for treatment of primary sclerosing cholangitis.
    Carey EJ; Eaton J; Clayton M; Gossard A; Iqbal S; Ullah H; Zhang N; Butterfield R; Lindor KD
    Hepatol Commun; 2022 Jul; 6(7):1589-1597. PubMed ID: 35238498
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathogenesis and Management of Pruritus in PBC and PSC.
    Kremer AE; Namer B; Bolier R; Fischer MJ; Oude Elferink RP; Beuers U
    Dig Dis; 2015; 33 Suppl 2():164-75. PubMed ID: 26641452
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cilofexor in Patients With Compensated Cirrhosis Due to Primary Sclerosing Cholangitis: An Open-Label Phase 1B Study.
    Levy C; Caldwell S; Mantry P; Luketic V; Landis CS; Huang J; Mena E; Maheshwari R; Rank K; Xu J; Malkov VA; Billin AN; Liu X; Lu X; Barchuk WT; Watkins TR; Chung C; Myers RP; Kowdley KV
    Clin Transl Gastroenterol; 2024 Aug; 15(8):e00744. PubMed ID: 38976363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maralixibat Treatment Response in Alagille Syndrome is Associated with Improved Health-Related Quality of Life.
    Kamath BM; Goldstein A; Howard R; Garner W; Vig P; Marden JR; Billmyer E; Anderson A; Kirson N; Jacquemin E; Gonzales E
    J Pediatr; 2023 Jan; 252():68-75.e5. PubMed ID: 36096175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience.
    Lemoinne S; Pares A; Reig A; Ben Belkacem K; Kemgang Fankem AD; Gaouar F; Poupon R; Housset C; Corpechot C; Chazouillères O
    Clin Res Hepatol Gastroenterol; 2018 Dec; 42(6):521-528. PubMed ID: 30100231
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis - a pilot study.
    Martin CR; Blanco PG; Keach JC; Petz JL; Zaman MM; Bhaskar KR; Cluette-Brown JE; Gautam S; Sheth S; Afdhal NH; Lindor KD; Freedman SD
    Aliment Pharmacol Ther; 2012 Jan; 35(2):255-65. PubMed ID: 22129201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.